Analytical Data
-
基因名
Fc gamma RIIIA/CD16a
-
简介
The FcγRIIIA/CD16a protein is a receptor for IgG and is optimally activated upon binding of aggregated antigen-IgG complexes, inducing antibody-dependent cellular cytotoxicity (ADCC). It mediates IgG effector function on natural killer cells, limiting viral load. Fc gamma RIII/CD16 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Fc gamma RIII/CD16 protein, expressed by HEK293 , with C-His labeled tag.
- Application
-
生物活性
1. Measured by its binding ability in a SPR assay (Biacore T200). Rituximab captured on CM5 Chip via Protein A can bind Cynomolgus Fc gamma RIII with an affinity constant of 0.251 μM. 2. Measured by its binding ability in a functional ELISA. Immobilized Cynomolgus CD16 at 10 μg/mL (100 μL/well) can bind Biotinylated Human lgG1. The ED50 for this effect is 0.276 μg/mL, corresponding to a specific activity is 3.62×10^3 Unit/mg. Measured by its binding ability in a functional ELISA. Immobilized Cynomolgus CD16 at 10 μg/mL (100 μL/well) can bind Biotinylated Human lgG1. The ED50 for this effect is 0.276 μg/mL, corresponding to a specific activity is 3.62×103 Unit/mg.
-
别名
IgG Fc receptor III; Fc-gamma RIII; FcRIII; FCGR3; CD16; CD16A; FCG3; FcgRIII; FCR-10; FCRIIIA; IGFR3; IMD20
-
种属
Cynomolgus
-
表达系统
HEK293
-
标签
C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8SPW2
-
表达区间
G17-Q208
-
氨基酸序列
GMRAEDLPKAVVFLEPQWYRVLEKDRVTLKCQGAYSPEDNSTRWFHNESLISSQTSSYFIAAARVNNSGEYRCQTSLSTLSDPVQLEVHIGWLLLQAPRWVFKEEESIHLRCHSWKNTLLHKVTYLQNGKGRKYFHQNSDFYIPKATLKDSGSYFCRGLIGSKNVSSETVNITITQDLAVSSISSFFPPGYQ
-
蛋白长度
Extracellular Domain
-
分子量
33-40 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Fc gamma RIIIA (CD16a) is a crucial receptor expressed on the surface of natural killer (NK) cells and some immune cell types, playing a significant role in mediating antibody-dependent cellular cytotoxicity (ADCC). This receptor binds to the Fc region of IgG antibodies, facilitating the immune system's ability to target and eliminate infected or malignant cells. Due to its critical role in immune response, CD16a has attracted considerable attention in immunotherapy, particularly in the development of monoclonal antibodies for cancer treatment. Researchers have been investigating the structure and function of recombinant CD16a proteins to better understand its binding affinities, signaling mechanisms, and potential modifications that could enhance its therapeutic efficacy. Studies have shown that optimizing the glycosylation patterns of CD16a can improve its interaction with antibodies, thus enhancing immune response. Additionally, recombinant CD16a proteins serve as valuable tools in clinical studies and drug development, allowing scientists to explore their use in combination therapies that harness the power of the immune system to combat tumors. The growing body of research surrounding Fc gamma RIIIA/CD16a underscores its potential as a target for novel immunotherapeutic strategies, aiming to improve patient outcomes in cancer and infectious diseases.
